Emisphere Technologies has reported encouraged findings from a clinical study assessing the oral delivery of GLP-1 peptide safely and effectively.
The study, conducted in 16 healthy male subjects, was designed to explore the pharmacodynamic effects of a single oral dose of GLP-1 administered 15 minutes prior to an oral glucose tolerance test. The study used a delivery-agent-based approach using Emisphere’s Eligen technology, and was conducted at University Hospital in Basel, Switzerland.
For the study, GLP-1 was formulated as a tablet with Emisphere’s delivery agent known as SNAC. The study also showed that pharmacological levels were achieved after a 2mg oral dose. The study demonstrated that the oral formulation of GLP-1 stimulated an early increase in fasting insulin and a decrease in fasting glucose as compared to placebo.
Emisphere’s Eligen technology is based on the development of small organic molecules, termed delivery agents or carriers, which interact non-covalently with macromolecules to enable their oral absorption.
Michael Novinski, president and CEO of Emisphere, said: “The study provides yet further evidence in the application of our Eligen technology as a potential solution to critical hurdles in pharmaceutical development. Hopefully, its use with GLP-1 in the treatment of diabetes will improve healthcare for millions of patients.”
Comments